24047-22-1

Upstream product

• 83-38-5 2,6-dichlorobenzaldehyde 
• 79-19-6 thiosemicarbazide 

Downstream Products

• 134951-65-8 [2-(2,6-Dichloro-phenyl)-4-oxo-thiazolidin-3-yl]-thiourea 
• 467246-10-2 C₂₀H₁₃Cl₂N₃S 
• 134951-64-7 2-(2,6-Dichloro-phenyl)-3-[4-oxo-thiazolidin-(2E)-ylideneamino]-thiazolidin-4-one 
• 134951-69-2 6-(2,6-Dichloro-phenyl)-1,5-dithia-3a,6a,7-triaza-cyclopenta[a]pentalen-3-one 
• 65871-56-9 2-(2,6-dichloro-phenyl)-5-hydrazino-[1,3,4]thiadiazole 
• 113111-56-1 2-Chloro-5-(2,6-dichloro-phenyl)-[1,3,4]thiadiazole 
• 134951-63-6 2-{[1-(2,6-Dichloro-phenyl)-meth-(E)-ylidene]-hydrazono}-thiazolidin-4-one 
• 89978-31-4 5-(2,6-dichlorophenyl)-1,3,4-thiadiazol-2-amine 

Relevant academic research and scientific papers

Novel 4-thiazolidinones as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase

In continuation of our efforts to develop new derivatives as hepatitis C virus (HCV) NS5B inhibitors, we synthesized novel 5-arylidene-4-thiazolidinones. The novel compounds 29-42, together with their synthetic precursors 22-28, were tested for HCV NS5B inhibitory activity; 12 of these compounds displayed IC50 values between 25.3 and 54.1 μM. Compound 33, an arylidene derivative, was found to be the most active compound in this series with an IC50 value of 25.3 μM. Molecular docking studies were performed on the thumb pocket-II of NS5B to postulate the binding mode for these compounds.

Synthesis, Antileishmanial Activity and In Silico Studies of Aminoguanidine Hydrazones (AGH) and Thiosemicarbazones (TSC) Against Leishmania chagasi Amastigotes

Background: Leishmaniasis is a worldwide health problem, highly endemic in developing countries. Among the four main clinical forms of the disease, visceral leishmaniasis is the most se-vere, fatal in 95% of cases. The undesired side-effects from first-li

Microwave-assisted synthesis and antitumor evaluation of a new series of thiazolylcoumarin derivatives

A new series of thiazolylcoumarin derivatives was synthesized. The designed strategy embraced a molecular hybridization approach which involves the combination of the thiazole and coumarin pharmacophores together. The new hybrid compounds were tested for

Synthesis, bioevaluation and docking study of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents

Since the first histone deacetylase (HDAC) inhibitor (Zolinza, widely known as suberoylanilide hydroxamic acid; SAHA) was approved by the Food and Drug Administration for the treatment of T-cell lymphoma in 2006, the search for newer HDAC inhibitors has attracted a great deal of interest of medicinal chemists worldwide. As a continuity of our ongoing research in this area, we designed and synthesized a series of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as analogues of SAHA and evaluated their biological activities. A number of compounds in this series, for example, N1-hydroxy-N8-(5-(2-chlorophenyl)-1,3,4-thiadiazol-2-yl)octandiamide (5b), N1-hydroxy-N8-(5-(3-chlorophenyl-1,3,4-thiadiazol-2-yl)octandiamide (5c) and N1-hydroxy-N8-(5-(4-chlorophenyl)-1,3,4-thiadiazol-2-yl)octandiamide (5d), were found to possess potent anticancer cytotoxicity and HDAC inhibition effects. Compounds 5b-d were generally two- to five-fold more potent in terms of cytotoxicity compared to SAHA against five cancer cell lines tested. Docking studies revealed that these hydroxamic acid displayed higher affinities than SAHA toward HDAC8.